SINOPHARM GROUP (Germany) Performance
| X2S1 Stock | EUR 13.10 0.20 1.55% |
On a scale of 0 to 100, SINOPHARM GROUP holds a performance score of 14. The entity has a beta of 0.77, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, SINOPHARM GROUP's returns are expected to increase less than the market. However, during the bear market, the loss of holding SINOPHARM GROUP is expected to be smaller as well. Please check SINOPHARM GROUP's total risk alpha, treynor ratio, value at risk, as well as the relationship between the sortino ratio and maximum drawdown , to make a quick decision on whether SINOPHARM GROUP's existing price patterns will revert.
Risk-Adjusted Performance
14 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in SINOPHARM GROUP 15ON are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, SINOPHARM GROUP reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Price Earnings Ratio | 6.3842 | |
| Dividend Yield | 0.0492 | |
| Payout Ratio | 0.2955 |
SINOPHARM |
SINOPHARM GROUP Relative Risk vs. Return Landscape
If you would invest 970.00 in SINOPHARM GROUP 15ON on September 23, 2024 and sell it today you would earn a total of 340.00 from holding SINOPHARM GROUP 15ON or generate 35.05% return on investment over 90 days. SINOPHARM GROUP 15ON is generating 0.4933% of daily returns assuming 2.7431% volatility of returns over the 90 days investment horizon. Simply put, 24% of all stocks have less volatile historical return distribution than SINOPHARM GROUP, and 91% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
SINOPHARM GROUP Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SINOPHARM GROUP's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as SINOPHARM GROUP 15ON, and traders can use it to determine the average amount a SINOPHARM GROUP's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1798
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | X2S1 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.74 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.49 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average SINOPHARM GROUP is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SINOPHARM GROUP by adding it to a well-diversified portfolio.
SINOPHARM GROUP Fundamentals Growth
SINOPHARM Stock prices reflect investors' perceptions of the future prospects and financial health of SINOPHARM GROUP, and SINOPHARM GROUP fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SINOPHARM Stock performance.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Shares Outstanding | 624.13 M | |||
| Price To Earning | 7.03 X | |||
| Revenue | 546.15 B | |||
| EBITDA | 23.5 B | |||
| Cash And Equivalents | 34.36 B | |||
| Cash Per Share | 55.05 X | |||
| Total Debt | 86.79 B | |||
| Debt To Equity | 0.93 % | |||
| Book Value Per Share | 105.05 X | |||
| Earnings Per Share | 1.77 X | |||
About SINOPHARM GROUP Performance
By analyzing SINOPHARM GROUP's fundamental ratios, stakeholders can gain valuable insights into SINOPHARM GROUP's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if SINOPHARM GROUP has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if SINOPHARM GROUP has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the Peoples Republic of China. The company was founded in 2003 and is headquartered in Shanghai, the Peoples Republic of China. SINOPHARM GROUP operates under Medical Distribution classification in Germany and is traded on Frankfurt Stock Exchange. It employs 108370 people.Things to note about SINOPHARM GROUP 15ON performance evaluation
Checking the ongoing alerts about SINOPHARM GROUP for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SINOPHARM GROUP 15ON help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Evaluating SINOPHARM GROUP's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate SINOPHARM GROUP's stock performance include:- Analyzing SINOPHARM GROUP's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SINOPHARM GROUP's stock is overvalued or undervalued compared to its peers.
- Examining SINOPHARM GROUP's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SINOPHARM GROUP's management team can have a significant impact on its success or failure. Reviewing the track record and experience of SINOPHARM GROUP's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SINOPHARM GROUP's stock. These opinions can provide insight into SINOPHARM GROUP's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for SINOPHARM Stock analysis
When running SINOPHARM GROUP's price analysis, check to measure SINOPHARM GROUP's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SINOPHARM GROUP is operating at the current time. Most of SINOPHARM GROUP's value examination focuses on studying past and present price action to predict the probability of SINOPHARM GROUP's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SINOPHARM GROUP's price. Additionally, you may evaluate how the addition of SINOPHARM GROUP to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |